Evidence map›Paper›PMID 34838195›Full record

ArticleThe Lancet. Public health2021

The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study.

Ling Yang, Christiana Kartsonaki, Pang Yao, Catherine de Martel, Martyn Plummer, Daniel Chapman, Yu Guo, Sarah Clark, Robin G Walters, Yiping Chen and 13 more

Open access · goldAbstract read
In one paragraph

Article in The Lancet. Public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 9 pooled it
28.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 9 syntheses or guidelines pooled it, 186 citations in OpenAlex.

  1. Burden of gastric cancer attributable to Helicobacter pylori in 27 countries from seven geographic regions in 2022.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Pooled it
  2. Social determinants of health andFrontiers in public health · 2025
    Pooled it
  3. Guideline
  4. Frontiers in medicine · 2024
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Native and Indigenous Populations and Gastric Cancer: A Worldwide Review.International journal of environmental research and public health · 2022
    Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Genes · 2026
    Article
  15. Trends inThe Lancet regional health. Western Pacific · 2026
    Article
  16. Article
  17. Simultaneous point-of-care detection and virulence typing of Helicobacter pylori using multiplex recombinase polymerase amplification combined with lateral flow strip.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  18. Review
  19. Review
  20. Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 5 countries.

Ling YangClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address: ling.yang@ndph.ox.ac.uk.
Christiana KartsonakiClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Pang YaoClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Catherine de MartelEarly Detection, Prevention, and Infections Branch, International Agency for Research on Cancer, Lyon, France.
Martyn PlummerDepartment of Statistics, University of Warwick, Coventry, UK.
Daniel ChapmanClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Yu GuoChinese Academy of Medical Sciences, Dong Cheng District, Beijing, China.
Sarah ClarkClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Robin G WaltersClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Yiping ChenClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Pei PeiChinese Academy of Medical Sciences, Dong Cheng District, Beijing, China.
Jun LvDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing, China.
Canqing YuDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing, China.
Rima JeskeInfections and Cancer Epidemiology Division, German Cancer Research Centre, Heidelberg, Germany.
Tim WaterboerInfections and Cancer Epidemiology Division, German Cancer Research Centre, Heidelberg, Germany.
Gary M CliffordEarly Detection, Prevention, and Infections Branch, International Agency for Research on Cancer, Lyon, France.
Silvia FranceschiCentro di Riferimento Oncologico IRCCS, Aviano, Italy.
Richard PetoClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Michael HillClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Liming LiDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing, China.
Iona Y MillwoodClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Zhengming ChenClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
China Kadoorie Biobank Collaborative Group
Peking University · CNUniversity of Oxford · GBCentre International de Recherche sur le Cancer · FRChinese Academy of Medical Sciences & Peking Union Medical College · CNGerman Cancer Research Center · DEIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Warwick · GB

Funding

Cancer Research UK 16896Cancer Research UK 24504Cancer Research UK 29186Medical Research Council MC_U137686851Medical Research Council MC_UU_00017/1Medical Research Council MC_UU_12026/2Wellcome TrustWorld Health Organization 001
6 · The paper itself

Abstract

backgroundHelicobacter pylori infection is a major cause of non-cardia gastric cancer (NCGC), but its causal role in cardia gastric cancer (CGC) is unclear. Moreover, the reported magnitude of association with NCGC varies considerably, leading to uncertainty about population-based H pylori screening and eradication strategies in high-risk settings, particularly in China, where approximately half of all global gastric cancer cases occur. Our aim was to assess the associations of H pylori infection, both overall and for individual infection biomarkers, with the risks of NCGC and CGC in Chinese adults.

methodsA case-cohort study was done in adults from the prospective China Kadoorie Biobank study, aged 30-79 years from ten areas in China (Qingdao, Haikou, Harbin, Suzhou, Liuzhou, Henan, Sichuan, Hunan, Gansu, and Zhejiang), and included 500 incident NCGC cases, 437 incident CGC cases, and 500 subcohort participants who were cancer-free and alive within the first two years since enrolment in 2004-08. H pylori biomarkers were measured in stored baseline plasma samples using a sensitive immunoblot assay (HelicoBlot 2.1), with adapted criteria to define H pylori seropositivity. Cox regression was used to estimate adjusted hazard ratios (HRs) for NCGC and CGC associated with H pylori infection. These values were used to estimate the number of gastric cancer cases attributable to H pylori infection in China.

findingsOf the 512 715 adults enrolled in the China Kadoorie Biobank between June, 2004, and July, 2008, 500 incident NCGC cases, 437 incident CGC cases, and 500 subcohort participants were selected for analysis. The seroprevalence of H pylori was 94·4% (95% CI 92·4-96·4) in NGCG, 92·2% (89·7-94·7) in CGC, and 75·6% (71·8-79·4) in subcohort participants. H pylori infection was associated with adjusted HRs of 5·94 (95% CI 3·25-10·86) for NCGC and 3·06 (1·54-6·10) for CGC. Among the seven individual infection biomarkers, cytotoxin-associated antigen had the highest HRs for both NCGC (HR 4·41, 95% CI 2·60-7·50) and CGC (2·94, 1·53-5·68). In this population, 78·5% of NCGC and 62·1% of CGC cases could be attributable to H pylori infection. H pylori infection accounted for an estimated 339 955 cases of gastric cancer in China in 2018.

interpretationAmong Chinese adults, H pylori infection is common and is the cause of large numbers of gastric cancer cases. Population-based mass screening and the eradication of H pylori should be considered to reduce the burden of gastric cancer in high-risk settings.

fundingCancer Research UK, Wellcome Trust, UK Medical Research Council, British Heart Foundation, Kadoorie Charitable Foundation, National Key Research and Development Program of China, and National Natural Science Foundation of China.

Indexed as

Helicobacter pyloriAgedBiological Specimen BanksBiomarkersCardiaChinaCohort StudiesFemaleHelicobacter InfectionsHumansImmunoblottingMaleMiddle AgedOdds RatioProportional Hazards ModelsProspective StudiesBiomarkers

Identifiers

PMID34838195
PMCPMC8646857
OpenAlexW3186154005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.